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A B S T R A C T
Background: Enzyme replacement therapy (ERT) with recombinant human α-galactosidase has been available
for the treatment of Fabry disease since 2001 in Europe and 2003 in the USA. Treatment outcomes with ERT are
dependent on baseline patient characteristics, and published data are derived from heterogeneous study po-
pulations.
Methods: We conducted a comprehensive systematic literature review of all original articles on ERT in the
treatment of Fabry disease published up until January 2017. This article presents the findings in adult male
patients.
Results: Clinical evidence for the efficacy of ERT in adult male patients was available from 166 publications
including 36 clinical trial publications. ERT significantly decreases globotriaosylceramide levels in plasma,
urine, and in different kidney, heart, and skin cell types, slows the decline in estimated glomerular filtration rate,
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and reduces/stabilizes left ventricular mass and cardiac wall thickness. ERT also improves nervous system,
gastrointestinal, pain, and quality of life outcomes.
Conclusions: ERT is a disease-specific treatment for patients with Fabry disease that may provide clinical benefits
on several outcomes and organ systems. Better outcomes may be observed when treatment is started at an early
age prior to the development of organ damage such as chronic kidney disease or cardiac fibrosis. Consolidated
evidence suggests a dose effect. Data described in male patients, together with female and paediatric data,
informs clinical practice and therapeutic goals for individualized treatment.
1. Introduction
Fabry disease (OMIM #301500) is an X-linked lysosomal storage
disorder caused by pathogenic variants in the GLA gene (OMIM
#300644; HGNC 4296) encoding the lysosomal enzyme α-galactosidase
[1]. Subsequent accumulation of the glycosphingolipid globo-
triaosylceramide (GL-3) and its derivative globotriaosylsphingosine
(lyso-GL-3) in cells, plasma, and urine causes progressive tissue damage
in affected organs, resulting in multisystemic disease, life-threatening
complications, and a reduced life expectancy in both males and females
[2].
Fabry disease has a wide range of clinical presentations ranging
from the early-onset ‘classic’ severe phenotype in patients with absent
or severely decreased α-galactosidase activity, to later-onset ‘non-
classic’ phenotypes often affecting a single organ system in patients
with higher levels of residual α-galactosidase activity [1,3,4]. Patients
with the classic phenotype, who are mostly males, generally experience
signs and symptoms from early childhood onwards such as neuropathic
pain, gastrointestinal (GI) disturbance, and hypohidrosis (all likely due
to peripheral and autonomic nervous system [PNS, ANS] involvement),
progressing to multi-organ failure involving the kidneys (albuminuria,
proteinuria, decline in glomerular filtration rate [GFR], kidney failure),
heart (left ventricular hypertrophy [LVH], heart failure, conduct ab-
normalities, and arrhythmias), auditory/vestibular system (hearing
loss), and central nervous system (CNS) (stroke) in adulthood [1,5–15].
Enzyme replacement therapy (ERT) with recombinant α-galactosi-
dase was approved in Europe in 2001. There are two preparations
available: agalsidase alfa (Replagal®) administered at the licensed dose
of 0.2 mg/kg; and agalsidase beta (Fabrazyme®) administered at the
licensed dose of 1 mg/kg body weight. Both preparations are ad-
ministered intravenously every other week (EOW) [16,17]. Agalsidase
alfa and agalsidase beta are available in most European countries, and
in Asia, Australia, and Canada. Agalsidase beta was approved by the US
Food and Drug Administration in 2003.
Although ERT has been in clinical use since 2001, many questions
remain regarding treatment initiation timing, optimal dose, and treat-
ment goals [1,17]. This is important as ERT in Fabry disease is ex-
pensive and is a lifelong commitment for patients. Traditionally used
methods for analysing pooled data such as meta-analysis and meta-
syntheses are difficult to apply in rare disease settings [18–20] and a
systematic literature analysis including real-life experiences may be the
best tool with which to provide a comprehensive overview of published
clinical evidence.
We conducted a comprehensive systematic literature review of all
original articles on ERT in the treatment of Fabry disease published up
until January 2017 [21]. This article presents an analysis of treatment
outcomes in adult male patients.
2. Methods
The full methodology for the systematic literature searches that
were performed has been published in this issue [21], together with
papers summarizing the findings of the literature review in female [22]
and paediatric patients [23], and a position statement on therapeutic
goals in Fabry disease based on the conclusions of an expert consensus
panel [24]. The original searches included articles published up to and
including January 2017.
The outcomes that were selected for analysis included plasma and
urine GL-3 and lyso-GL-3 levels, GL-3 histology, measures of renal and
cardiac function and of cardiac morphology. Other outcomes included
ANS, PNS, and CNS parameters, GI symptoms, pain, and quality of life
(QoL). GL-3 levels were described as ‘normalized’ if they were higher
than reference values at baseline and decreased to within reference
values during treatment, and if they were described as being normal-
ized in the publication; note that the reference values varied in each
publication.
Results are described for the approved dose regimens agalsidase alfa
0.2 mg/kg EOW and agalsidase beta 1.0 mg/kg EOW. Specific note has
been made of altered dose regimens due to the temporary shortage of
agalsidase beta to examine the efficacy of reduced-dose ERT [198].
Publications describing studies in which data from patients treated with
agalsidase alfa and agalsidase beta were combined or in which the ERT
type was not specified are referred to in the analysis as ‘mixed-ERT’
publications.
3. Results
3.1. Adult male population and publication overview
The publications that reported ERT outcomes data specific for adult
male patients and that were included in the systematic literature ana-
lysis are summarized in Supplementary Table 1a. Publications were
available from clinical trials (CT), observational study (OS) publica-
tions, studies describing both treatments, a combination of treatments,
or when treatment was not specified (i.e. mixed-ERT studies), studies
including both genders but with at least 50% male patients (i.e. mixed-
gender [MG] studies), and case reports (CR).
For agalsidase alfa there were 16 CT publications (including five
publications derived from Grade 1a randomized controlled trials
[RCTs], nine publications from Grade 1c single-arm CTs and two from
Grade 1a/c studies; four were placebo-controlled studies), 15 OS pub-
lications (of which six covered Grade 2 prospective OS publications,
and nine Grade 3 retrospective OS publications) and 13 CRs (three
Grade 4 case series and 10 Grade 5 CRs). For agalsidase beta, there were
five CT publications (all Grade 1c single-arm CTs), 11 OS publications
(four Grade 2 prospective OS publications, and seven Grade 3 retro-
spective OS publications) and 17 CRs (four Grade 4 case series and 13
Grade 5 CRs). There were no CT publications, 18 OS publications (seven
Grade 2 prospective OS publications, and 11 Grade 3 retrospective OS
publications), and 19 CRs (five Grade 4 case series and 12 publications
which were either Grade 5 CRs or reported baseline and follow-up data
on a single patient) describing mixed ERT, a comparison between
agalsidase alfa and agalsidase beta, or not specifying the type of ERT.
The publications that reported ERT outcomes data for MG pub-
lications are summarized in Supplementary Table 1b. For agalsidase
alfa there were five CT publications (two from Grade 1a RCTs, two from
Grade 1c single-arm CTs and one from a Grade 1a/c study [1a portion
was placebo-controlled]), 11 OS publications (five from Grade 2 pro-
spective OS publications, and six from Grade 3 retrospective OS pub-
lications), and no CRs. For agalsidase beta, there were ten CT pub-
lications (one placebo-controlled Grade 1a RCT, seven Grade 1c single-
arm CTs [including four open-label extension studies of the RCT] and
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Table 1
Summary of outcomes with agalsidase beta 1.0 mg/kg EOW or agalsidase alfa 0.2 mg/kg EOW from clinical and observational studies of adult male patients with
Fabry disease
Outcome Agalsidase alfa 0.2 mg/kg EOW Agalsidase beta 1.0 mg/kg EOW
3.2. GL-3 and lyso-GL-3 accumulation
3.2.1. Plasma GL-3 ↓ Significant (Clarke et al. 2007 [25]; Pastores et al. 2007 [35];
Schiffmann et al. 2006 [39]; Schiffmann et al. 2007 [52]; van Breemen
et al. 2011 [102])
↓ Significance unknown (Goker-Alpan et al. 2015 [26]; Goláň et al.
2015 [27]; Hughes et al. 2008 [29]; Schiffmann et al. 2001 [36];
Rombach et al. 2012 [101])
– No change (Goker-Alpan et al. 2015 [26 (switch study)])
↓ Significant (Eto et al. 2005 [70]; Goker-Alpan et al. 2016 [71
(switch study)]; Lubanda et al. 2009 [72]; Elliott et al. 2006
[76]; van Breemen et al. 2011 [102])
↓ Non-significant (Bénichou et al. 2009 [75]; Mignani et al.
2004 [80])
↓ Unknown significance (Eng et al. 2001 [69]; Rombach et al.
2012 [101])
3.2.2. Plasma lyso-GL-3 ↓ Significant (Goker-Alpan et al. 2015 [26 (switch study)])
↓ Unknown significance (Rombach et al. 2012 [101]; van Breemen
et al. 2011 [102])
↑ Significant (Smid et al. 2011 [54 (switch study)])
↓ Significant (Goker-Alpan et al. 2016 [71 (switch study)])
↓ Unknown significance (Rombach et al. 2012 [101]; van
Breemen et al. 2011 [102])
3.2.3. Urinary GL-3 ↓ Significant (Goker-Alpan et al. 2015 [26 (12 months)]; Hughes et al.
2008 [29 (6 months)]; Schiffmann et al. 2001 [36]; Schiffmann et al.
2006 [38]; Schiffmann et al. 2007 [52])
↓ Unknown significance (Pastores et al. 2007 [35 (1/12 pts)]; Whitfield
et al. 2005 [55]; Rombach et al. 2012 [101])
↑ Non-significant (Goker-Alpan et al. 2015 [26 (switch study)])
↓ Significant (Lubanda et al. 2009 [72])
↓ Non-significant (Eto et al. 2005 [70]; Goker-Alpan et al. 2016
[71 (switch study)])
↓ Unknown significance (Rombach et al. 2012 [101])
– No change (Mignani et al. 2004 [80])
3.2.4. Urinary lyso-GL-3 No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational studies with approved
dose of agalsidase beta
3.2.5. GL-3 accumulation: histology
3.2.5.1. Renal cells ↓ Non-significant (Schiffmann et al. 2001 [36]) ↓Significant (Lubanda et al. 2009 [72]; Najafian et al. 2016 [73
(proportion of podocytes without GL-3 inclusions)])
↓ Non-significant (Eng et al. 2001 [69]; Najafian et al. 2016
[73 (volume of GL-3 inclusions/podocyte and podocyte GL-3
score)])
3.2.5.2. Cardiac cells ↓ Significance unknown (Hughes et al. 2008 [29]) ↓ Significance unknown (Eng et al. 2001 [69])
3.2.5.3. Other cell types No data from clinical or observational studies
with approved dose of agalsidase alfa
↓ Significance unknown (Eng et al. 2001 [69]; Lubanda et al.
2009 [72]; Bénichou et al. 2009 [75])
3.3. Renal outcomes
3.3.1. eGFR ↑ Significant (Hughes et al. 2008 [29])
Significantly slower decline (vs placebo, creatinine clearance
(Schiffmann et al. 2001 [36])
↓ Significant (Schiffmann et al. 2006 [39]; Feriozzi et al. 2009 [43];
Feriozzi et al. 2012 [44]; Hughes et al. 2011 [48]; Schiffmann et al.
2007 [52])
↓ Non-significant (Schiffmann et al. 2006 [38]; Smid et al. 2011 [54
(switch study)])
↓ Unknown significance (Beck et al. 2015 [41])
– No change (Kampmann et al. 2015 [49])
↓ Non-significant (Eto et al. 2005 [70])
↓ Significance unknown, reduced decline (Warnock et al. 2012
[82])
↓ Significance unknown (Kim et al. 2016 [79])
– No change (Lubanda et al. 2009 [72])
3.3.2. Albuminuria/
Proteinuria
↑ Significant, CKD1 pts (Feriozzi et al. 2012 [44]; Kampmann et al.
2015 [49 (pts with baseline proteinuria)])
↑ Unknown significance (Schiffmann et al. 2006 [39])
↓ Non-significant (Bongiorno et al. 2003 [42])
– No change, stabilization (Schiffmann et al. 2001 [36]; Feriozzi et al.
2009 [43]; Feriozzi et al. 2012 [44 (CKD2/3)]; Hughes et al. 2011
[48]; Kampmann et al. 2015 [49 (pts without baseline proteinuria)];
Schiffmann et al. 2007 [52])
– No change (Lubanda et al. 2009 [72]; Kim et al. 2016 [79])
↓ Non-significant (Najafian et al. 2016 [73])
3.4. Cardiac outcomes
3.4.1. LVM/LVMi ↓ Significant improvement (Hughes et al. 2008 [29]; Hughes et al.
2011 [48 (pts with baseline LVH]); Kampmann et al. 2015 [49 (pts
with baseline LVH)])
↓ Improvement of unknown significance (Tsuboi et al. 2012 [189])
↑ Significant (Beck et al. 2015 [41 (slowed progression)])
↑ Non-significant (Goláň et al. 2015 [27])
– No change (Kampmann et al. 2015 [49 (pts without baseline LVH)])
↓ Significant improvement (Germain et al. 2013 [7]; Motwani
et al. 2012 [81])
— No change (Elliott et al. 2006 [76]; Kim et al. 2016 [79];
Mignani et al. 2004 [80])
3.4.2. LVWT ↓ Significant (Kampmann et al. 2015 [49])
↓ Improvement of unknown significance (Tsuboi et al. 2012 [189])
↓ Significant (Motwani et al. 2012 [81])
↓ Non-significant (Mignani et al. 2004 [80 (2/3 patients)])
↑ Non-significant (Mignani et al. 2004 [80 (1/3 patients)])
— No change (Elliott et al. 2006 [76])
3.4.3. LVEF – No change (Hughes et al. 2008 [29]; Kampmann et al. 2015 [49]) ↑ Significant (Motwani et al. 2012 [81])
↑ Non-significant improvement (Mignani et al. 2004 [80 (1/3
patients)])
3.4.4. ECG measures ↓ Significant improvement in QRS duration (Schiffmann et al. 2001
[36])
↓ Non-significant improvement in QRS duration (Hughes et al. 2008
[29])
– Conduction abnormality (Kampmann et al. 2015 [49 (1/21 pts)])
↑ Significant improvement in PQ interval, P-wave duration
(Motwani et al. 2012 [81])
↑ Significant improvement (Eng et al. 2001 [69])
↓ Significant improvement of QTc interval (Motwani et al.
2012 [81])
– No change (Mignani et al. 2004 [80])
3.4.5. Exercise testing No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational studies with approved
dose of agalsidase beta
(continued on next page)
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two Grade 1a/c studies [where the 1a portion was placebo-controlled]),
19 OS publications (16 Grade 2 prospective OS publications, and three
Grade 3 retrospective OS publications) and no CRs. For mixed ERT
there were two CT publications (one from a Grade 1a RCT and another
from a Grade 1c single-arm CT), 14 OS publications (nine from Grade 2
prospective OS publications, and five from Grade 3 retrospective OS
publications) and no CRs.
The main findings regarding clinical outcomes of treatment with
agalsidase alfa and agalsidase beta in male patients with Fabry disease
are summarized in Table 1.
3.2. GL-3 accumulation
3.2.1. Plasma GL-3
3.2.1.1. Agalsidase alfa 0.2 mg/kg EOW. Treatment with agalsidase alfa
was associated with a reduction in plasma GL-3 in four RCT
publications [25,27,29,36], of which the last two were placebo-
controlled, and four single-arm CT publications [26,35,39,40] (mainly
trials with ≤25 patients and follow-up periods of 2.5–54 months) and
three OS publications (including 12–22 male patients followed for
12–48 months) [52,101,102]. The change from baseline in plasma GL-3
was statistically significant in one RCT [25], one placebo-controlled
RCT with open-label extension [29], one placebo-controlled RCT [36]
and its open-label extension [39], one publication from a single-arm CT
[35] and two OS publications [52,102]. In both placebo-controlled
RCTs, there was a significant decrease in plasma GL-3 in the agalsidase
alfa arm compared with no changes in the placebo group [29,36]. There
were two publications that reported the impact of agalsidase dose/
regimen change [40,52]: in one single-arm CT publication [40], the
change from agalsidase alfa 0.2 mg/kg EOW to 0.2 mg/kg weekly
resulted in no change in plasma GL-3 compared with pre-switch levels,
whereas in another OS publication (12 patients followed for 24–48
months), further reductions, though not statistically significant, in
plasma GL-3 were observed when the dose was increased from 0.2
mg/kg EOW to 0.2 or 0.4 mg/kg weekly [52]. In one OS, the four
patients with antibodies to agalsidase alfa showed a reduction in
plasma GL-3 after 12 months [101] (Supplementary Table 2).
There were three RCT publications in MG populations
[27,135,176], one of which reported a significant decrease from base-
line in plasma GL-3 with agalsidase alfa 0.2 mg/kg EOW after 12
months [27,176]. One RCT publication reported non-significant re-
ductions from baseline in plasma GL-3 with agalsidase alfa 0.2 mg/kg
EOW and 0.2 mg/kg weekly regimens [27]; another RCT publication
described no statistically significant differences in plasma GL-3 reduc-
tions between for 0.2 mg/kg EOW, 0.1 mg/kg weekly, or 0.2 mg/kg
weekly schedules [135].
3.2.1.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, an overall
reduction in plasma GL-3 was reported in four single-arm CT
publications (involving 13–21 patients followed for 2.5 to>12
Table 1 (continued)
Outcome Agalsidase alfa 0.2 mg/kg EOW Agalsidase beta 1.0 mg/kg EOW
3.5. Nervous system outcomes
3.5.1. Sweat function ↑ Significant improvement, short-term (Schiffmann et al. 2003 [37])
↑ Non-significant improvement (Bongiorno et al. 2003 [42])
↑ Significance unknown (Hughes et al. 2011 [48])
— No change (Gupta et al. 2008 [45]; Schiffmann et al. 2007 [52])
↑ Subjective improvement (Eng et al. 2001 [69]; Hilz et al.
2004 [77])
3.5.2. PNS nerve sensitivity ↓ Significant improvement IENFD (Schiffmann et al. 2006 [38])
↓ Significant improvement cold/warm threshold (Schiffmann et al.
2003 [37])
— No change in cold/warm sensation (Schiffmann et al. 2006 [38])
— No change in neurological examination score (Jardim et al. 2004
[30]; Jardim et al. 2006 [31])
↓ Significant improvement (Hilz et al. 2004 [77])
3.5.3. Vestibular/auditory and
other CNS outcomes
↑ Significant improvement hearing loss (Hajioff et al. 2003 [28])
↑ Non-significant improvement peripheral vestibular function (Palla
et al. 2003 [34])
— Stabilization of hearing (Sergi et al. 2010 [53])
— No change, neurological examination (Jardim et al. 2004 [30])
↓ Significant improvement in cerebral blood flow (Moore et al. 2001
[32])
↓ Improvement of unknown significance in cerebral blood flow (Moore
et al. 2002 [33])
— No change, neurological examination (Hilz et al. 2004 [77])
3.5.4. White matter
hyperintensities
No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational studies with approved
dose of agalsidase beta
3.6. Pain outcomes ↓ Significant improvement (Schiffmann et al. 2001 [36]; Schiffmann
et al. 2003 [37]; Hoffmann et al. 2007 [47])
↓ Non-significant improvement in acroparesthesias (Jardim et al. 2006
[31]; Bongiorno et al. 2003 [42])
↓ Unknown significance, improvement (Bongiorno et al. 2003 [42])
— No change (Hughes et al. 2011 [48]; Sergi et al. 2010 [53];
Whitfield et al. 2005 [55])
↓ Significant improvement (Eng et al. 2001 [69]; Hilz et al.
2004 [77])
↓ Non-significant improvement (Eto et al. 2005 [70]; Mignani
et al. 2004 [80])
3.7. GI outcomes ↓ Unknown significance, improvement (Jardim et al. 2006 [31];
Hoffmann et al. 2007 [46]; Hughes et al. 2011 [48])
↑ Unknown significance, diarrhea (Hughes et al. 2011 [48];
No data from clinical or observational studies with approved
dose of agalsidase beta
3.8. QoL ↑ Non-significant improvement (Hughes et al. 2011 [48])
— No change, energy levels (Ghali et al. 2012 [100])
— No change, SF-36 (Smid et al. 2011 [54])
↑ Significant improvement (Eto et al. 2005 [70])
↑ Unknown significance (Eng et al. 2001 [69]; Watt et al. 2010
[83])
Results are summarized as increase (↑), decrease (↓) or no change from baseline to follow-up after ERT initiation. Significance refers to statistical significance. Results
are not adjusted for differences in study designs, patient characteristics, or disease stage. Case reports, mixed-ERT publications, and publications with other dose
regimens are not included.
CNS, central nervous system; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; EOW, every other week; GI, gastrointestinal; GL-3, globo-
triaosylceramide; IENFD, intra-epidermal nerve fibre density; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMi, left ventricular mass index;
LVWT, left ventricular wall thickness; lyso-GL-3, globotriaosylsphingosine; PNS, peripheral nervous system; pts, patients; QoL, quality of life; SF-36, 36-Item Short
Form Health Survey.
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months) [69–72], and five OS publications [75,76,80,101,102].
Agalsidase beta treatment resulted in normalization of plasma GL-3
levels in four publications (including three single-arm CTs [69,70,72]
and an OS publication [75]) and statistically significant reductions of
plasma GL-3 levels in five publications (three single-arm CTs [70–72]
and two OS publications [76,102]). In one single-arm CT, plasma GL-3
levels were above the normal range at baseline, decreased significantly
with the 1.0 mg/kg EOW dose to normal levels and remained stable
when the dose was reduced to 0.3 mg/kg EOW [72]. In another single-
arm CT, switching 15 patients from agalsidase alfa 0.2 mg/kg EOW
(mean duration 3.7 years; range 1.6–14 years) to agalsidase beta 1.0
mg/kg EOW for 6 months resulted in a statistically significant further
reduction in plasma GL-3 after switch [71]. Two OS publications
showed that treatment with agalsidase beta 1.0 mg/kg EOW resulted
in larger reductions in plasma GL-3 compared with agalsidase alfa 0.2
mg/kg EOW [100,101], of which one publication was able to
demonstrate a statistically significant difference between the two
treatment regimens [101]. The same publications also described that
a reduction in plasma GL-3 levels can be achieved with a lower dose of
agalsidase beta (0.2 mg/kg EOW) [101,102] (Supplementary Table 2).
The findings of reductions in plasma GL-3 were supported by three CRs
of patients treated with agalsidase beta [91,94,98].
For MG populations, there were nine publications that described the
changes in plasma GL-3 with agalsidase beta
[79,149,157,160,163,166,168,176,180]. These publications were de-
rived from one RCT [176], one placebo-controlled RCT with open-label
extension [149], a longer-term open-label extension study from the
same RCT [157] and one study in which patients were treated through
an RCT, its open-label extension and then followed further through a
registry [163] (58 patients followed for up to 120 months), and five OS
publications [79,160,166,168,180]. All these publications noted a
general trend towards normalization of plasma GL-3 levels. In the
placebo-controlled study, patients receiving agalsidase beta 1.0 mg/kg
EOW experienced a decrease in plasma GL-3 while those receiving
placebo experienced no change; the difference between groups was
statistically significant [149]. One RCT publication reported a statisti-
cally significant reduction in plasma GL-3 with agalsidase beta 0.2 mg/
kg EOW (in 36 patients followed for ≥12 months) [176]. One OS, in 19
patients followed for 60–126 months, described reduced plasma GL-3
levels after 3 months of agalsidase beta and normalization after 1–2
years [79].
3.2.1.3. Mixed ERT. The findings of reductions in plasma GL-3 were
supported by an OS which combined data for agalsidase alfa and
agalsidase beta [101], and two mixed-ERT CRs [120,133].
There was one relatively large mixed-ERT MG OS publication (52
patients followed for ≥12 months) which reported a statistically sig-
nificant decrease in plasma GL-3 for patients treated with agalsidase
alfa 0.2 mg/kg EOW or agalsidase beta 0.2 mg/kg EOW, and a non-
significant decrease for patients unresponsive to 0.2 mg/kg EOW of
either treatment who switched to agalsidase beta 1.0 mg/kg EOW
[180]. Decreasing plasma GL-3 levels were also reported in a mixed-
ERT OS publication involving 34 renal dialysis or transplant patients
followed for 45–48 months [186].
3.2.2. Plasma lyso-GL-3
3.2.2.1. Agalsidase alfa 0.2 mg/kg EOW. Plasma lyso-GL-3 levels
decreased significantly with agalsidase alfa in one single-arm CT
publication (with data reporting for 21 patients followed for 24
months) [26] and non-significantly in two OS publications (involving
22–29 patients followed for ≥12 months) [101,102]. In one OS
publication (with 14 male patients treated with agalsidase alfa for a
median of 11 months), a statistically significant increase in plasma lyso-
GL-3 levels was reported in patients who switched from agalsidase beta
1.0 mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW [54]. Lastly, plasma
lyso-GL-3 was reduced in the two classic patients from an OS
publication: one who received agalsidase alfa and one who switched
from agalsidase beta 1.0 mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW
[110] (Supplementary Table 3).
3.2.2.2. Agalsidase beta 1.0 mg/kg EOW. One single-arm CT publication
reported a statistically significant decrease in plasma lyso-GL-3 after
switching from agalsidase alfa 0.2 mg/kg EOW (mean 3.7 years, range
1.6–14 years) to agalsidase beta 1.0 mg/kg EOW (in 15 patients
followed for 6 months) [71]. Two OS publications (in 22–29 male
patients followed for ≥12 months) showed that the decrease in plasma
lyso-GL-3 was more notable with agalsidase beta 1.0 mg/kg EOW
compared with agalsidase alfa 0.2 mg/kg EOW [101,102]. Agalsidase
beta at a reduced dose of 0.2 mg/kg EOW led to a decrease in plasma
lyso-GL-3 in two OS publications [101,102], and a statistically
significant increase in plasma lyso-GL-3 in another [54]
(Supplementary Table 3). One CR also described a decrease in plasma
lyso-GL-3 with agalsidase beta [94].
3.2.2.3. Mixed ERT. Statistically significant reductions in plasma lyso-
GL-3 with mixed-ERT were reported in one CT publication [182], four
OS publications [51,101,102,109] and one CR [133].
3.2.3. Urinary GL-3
3.2.3.1. Agalsidase alfa 0.2 mg/kg EOW. One placebo-controlled RCT
[36], one placebo-controlled RCT with open-label extension [29] and
three single-arm CTs [26,35 and 39, where 39 is an extension study of
36] reported a decrease in urinary GL-3 levels with agalsidase alfa
(including 12–21 male patients followed for 6–54 months). In one of
the placebo-controlled RCTs, urinary GL-3 declined significantly
compared with the placebo group [29], and in the other, urinary GL-
3 levels decreased with agalsidase alfa but increased in the placebo
group [36]. One single-arm CT publication (including 12 patients
followed for ≤120 months) in which patients were switched from
agalsidase alfa 0.2 mg/kg EOW to the same dose weekly reported no
change in urinary GL-3 [40] and another small single-arm CT reported
an increase in urinary GL-3 upon switching from agalsidase beta 1.0
mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW [26]. There were two OS
publications (including 6–12 patients followed for 12–48 months)
[52,55], one of which noted further reductions in urinary GL-3 levels
when the regimen was changed from EOW to a weekly schedule [52].
Urinary GL-3 levels increased in antibody-positive patients in one OS
publication (including 29 patients followed for> 12 months) [101]
(Supplementary Table 4).
There were two RCT publications which reported urinary GL-3 le-
vels in MG populations: one reported an overall decrease [176], and the
other a trend towards decline, with agalsidase alfa 0.2 mg/kg weekly
[135]. In an OS publication, a decrease in urinary GL-3 in antibody-
negative patients, and an increase in urinary GL-3 in antibody-positive
patients was reported following treatment with agalsidase alfa 0.2 mg/
kg EOW (52 patients followed for ≥12 months) [180].
3.2.3.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, three
single-arm CT publications (including 13–21 patients followed for 6–18
months) showed a decrease in urinary GL-3 levels [70–72]. During one
single-arm trial, urinary GL-3 levels decreased significantly with
agalsidase beta 1.0 mg/kg EOW and then increased significantly
when the agalsidase beta dose was reduced [72]. In a separate single-
arm CT, there was a non-significant decrease in urinary GL-3 levels
after switching from agalsidase alfa 0.2 mg/kg EOW to agalsidase beta
1.0 mg/kg EOW [71]. In one OS publication, antibody-positive patients
showed a decrease in urinary GL-3 levels with both agalsidase beta 1.0
mg/kg EOW and 0.2 mg/kg EOW, whereas, with agalsidase alfa 0.2
mg/kg EOW, an increase was seen [101]. In another OS publication (in
three patients), urinary GL-3 remained normal throughout 18 months of
follow-up [80]. In a CR, urinary GL-3 decreased after 12 months [99]
(Supplementary Table 4).
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In MG populations, one RCT publication reported a non-significant
decrease in urinary GL-3 with agalsidase beta 0.2 mg/kg EOW [176]. In
two OS publications, there was a statistically significant decrease in
urinary GL-3 (11 patients followed for ≤27 months) [160]; and 52
patients followed for ≥12 months [180]). In one OS publication in 19
patients followed for 60–126 months, urinary GL-3 levels declined after
3 months and normalized within 3 years [79]. One OS publication re-
ported a decrease in urinary GL-3 with agalsidase beta 1.0 mg/kg EOW
in both antibody-negative and antibody-positive patients [180]; with
the agalsidase beta 0.2 mg/kg dose, there was a decline in urinary GL-3
in antibody-negative patients and an increase in antibody-positive pa-
tients [180].
3.2.3.3. Mixed ERT. One mixed-ERT study publication in males showed
reductions in urinary GL-3 [101]. For MG publications, urinary GL-3
levels were undetectable both at baseline and at endpoint in one OS
publication (in 34 renal dialysis and transplant patients followed for
45–48 months) [186]. A decrease in urinary GL-3 in antibody-negative
patients, and an increase in urinary GL-3 in antibody-positive patients
were reported in an OS involving 18 patients followed for 6–12 months
[178].
3.2.4. Urinary lyso-GL-3
3.2.4.1. Agalsidase alfa/beta. There were no publications reporting on
the change in urinary lyso-GL-3 following treatment with agalsidase
alfa or agalsidase beta.
3.2.4.2. Mixed ERT. Urinary lyso-GL-3 levels decreased during
treatment with mixed-ERT in one male patient followed for 30
months in the only publication that reported this outcome [106].
3.2.5. GL-3 accumulation: histology
3.2.5.1. Renal cells
3.2.5.1.1. Agalsidase alfa 0.2 mg/kg EOW. In one placebo-controlled
RCT publication, GL-3 in kidney biopsy samples was reduced from
baseline in both the agalsidase alfa and placebo groups [36]
(Supplementary Table 5).
3.2.5.1.2. Agalsidase beta 1.0 mg/kg EOW. Two single-arm CT
publications reported change in GL-3 levels across various renal
tissues [72,73]. One publication observed statistically significant
increases in the proportions of patients experiencing GL-3 clearance
in six of eight different renal cell types after 6 months of treatment.
Clearance levels were generally maintained when patients received the
0.3 mg/kg EOW dose during 18 months of treatment in a single-arm CT
[72]. A 73% decline in podocyte GL-3 content and a 63% reduction in
podocyte volume after 11–12 months of agalsidase beta was reported in
the other single-arm CT publication [73]. In the same publication, there
was a reduction in GL-3 score (in three of six patients) and a statistically
significant increase in the number of podocytes/biopsy without visible
GL-3 inclusions with agalsidase beta treatment [73]. Also, one single-
arm CT showed that the accumulation of GL-3 in kidney cells was
reduced with different dosing regimens in four of five patients after five
infusions (2.5 months) [69] (Supplementary Table 5). In one CR,
agalsidase beta decreased renal GL-3 deposits (histological analysis
based on specific staining for GL-3 in renal biopsy samples) [89]. In
another CR, the composite podocyte score was reduced with agalsidase
beta but increased after switching to agalsidase alfa [130].
Four MG publications reported GL-3 clearance in renal capillary and
non-capillary endothelial cells with agalsidase beta: the placebo-con-
trolled RCT [149], its secondary analysis [153], and its extension study
[150], and the OS [160]. In the placebo-controlled RCT, the proportion
of patients achieving GL-3 clearance from renal capillary endothelial
cells was significantly higher with agalsidase beta than with placebo
[149]. A secondary analysis of the same study reported that, compared
with placebo, significantly more patients treated with agalsidase beta
achieved GL-3 clearance from glomerular capillary endothelial cells,
arterial/arteriolar endothelial cells, mesangial cells, and interstitial
cells [153]. The difference in proportion of patients achieving clearance
was statistically significant compared with baseline in the open-label
extension study of the RCT (up to 54 months’ follow-up) [150] and one
small OS (in 11 patients followed for ≤27 months) [160].
3.2.5.1.3. Mixed ERT. One CR noted that the adult male patient
who started ERT at 18 years of age showed clearance of GL-3 deposits
from podocytes, yet the paediatric male patient who started ERT at 7
years of age showed better clearance [130].
3.2.5.2. Cardiac cells
3.2.5.2.1. Agalsidase alfa 0.2 mg/kg EOW. In one placebo-controlled
RCT with open-label extension, during the 6-month RCT phase the six
patients who were treated with agalsidase alfa showed a non-significant
reduction in GL-3 accumulation in myocardial cells while the eight
patients in the placebo group experienced an increase [29]
(Supplementary Table 6). A MG OS publication reported GL-3
accumulation in cardiomyocytes with agalsidase alfa (17 patients
followed for ≤40 months), but data for both pre- and post-ERT were
not available [143].
3.2.5.2.2. Agalsidase beta 1.0 mg/kg EOW. There was one single-
arm CT publication in male patients which reported a non-significant
decrease in the capillary endothelium GL-3 scores [69] (Supplementary
Table 6).
In MG publications of agalsidase beta, a reduction in GL-3 accu-
mulation in cardiac endothelial cells was reported in three publications:
one was a placebo-controlled RCT with open-label extension [149], and
two were longer-term open-label extensions of the same study (in-
cluding 58 patients followed for up to 54 months) [150,155]. In the
RCT, patients treated with agalsidase beta 1.0 mg/kg EOW experienced
a decrease in cardiac GL-3 deposits, while those in the placebo group,
experienced a small increase [149].
3.2.5.2.3. Mixed ERT. There were no publications from either male
or MG publications describing the effect of mixed-ERT regimens on
cardiac GL-3 levels.
3.2.5.3. Other cell types
3.2.5.3.1. Agalsidase alfa 0.2 mg/kg EOW. There were no
publications describing change from baseline following agalsidase alfa
treatment in GL-3 levels in other cell types.
3.2.5.3.2. Agalsidase beta 1.0 mg/kg EOW. One single-arm CT
publication (in 15 patients followed for ≤ 2.5 months) reported a
decrease in GL-3 levels in liver cells in each of the five dosing regimens
[69]. In another, skin GL-3 was significantly reduced in 21 patients
followed for 6 months [72]. One single-arm study found that 100% of
patients had clearance of GL-3 in interstitial capillary endothelial cells
with agalsidase beta 1.0 mg/kg EOW but 90% with the reduced dose of
agalsidase beta 0.3 mg/kg [72]. In one OS publication, treatment
achieved GL-3 clearance from skin (as measured by an increase in the
number of patients with undetectable/trace levels of skin GL-3
following treatment) [75] (Supplementary Table 7). CRs described
clearance of glycolipid storage deposits from sweat glands [97] and
vascular endothelial cells [93].
In MG publications, one placebo-controlled RCT followed by open-
label extension (in 58 patients) reported a statistically significant re-
duction in skin epithelial GL-3 scores compared with placebo after 5
months, and during the open-label extension (after 6–12 months follow-
up), 96% of patients had total clearance of skin epithelial GL-3 [149].
These low levels were sustained in three further open-label extensions
of the same study (after 30-36 months [154,157] and after 54 months
[150]).
3.2.5.3.3. Mixed ERT. There were no publications for mixed-ERT
regimens describing other organ GL-3 levels.
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3.3. Renal outcomes
3.3.1. Estimated glomerular filtration rate (eGFR)
3.3.1.1. Agalsidase alfa 0.2 mg/kg EOW. For agalsidase alfa, eGFR was
reported as a measure of kidney function during ERT in six CT
publications (including one placebo-controlled RCT with open-label
extension [29], one placebo-controlled RCT [36] and its two extension
studies [38,39], and two single-arm studies [35,40]) and seven OS
publications [41,43,44,48,49,52,54]. In the placebo-controlled RCT,
renal function declined significantly more in the placebo group than in
the agalsidase alfa group [36]. In one placebo-controlled RCT with
open-label extension, eGFR was significantly increased compared with
baseline in the seven patients receiving agalsidase alfa, while the
patients receiving placebo experienced no changes [29]. Another
single-arm CT publication (in 12 patients) noted an increase in eGFR
after 6 months but this was not statistically significant [35]. The decline
in eGFR appeared to be slowed compared with placebo or untreated
patients when the 14 agalsidase alfa-treated patients from the placebo-
controlled RCT [36] were followed for 48–54 months [39], in a large
OS (in 360 patients, of whom 115 male patients had eGFR data,
followed for 60 months) [41], and in a small OS (in 12 patients
followed for 24–48 months) [52]. Other publications showed decreases
in eGFR, including one open-label extension of a placebo-controlled
RCT (in 26 patients followed for 12–18 months) [38], three
publications from the same registry (including 115–172 patients
followed for 36–134 months) [43,44,48], and one OS (in 15 patients
treated for a median of 11 months with agalsidase alfa [54]). Another
single-arm CT publication reported a slowed decline in eGFR on
switching from agalsidase alfa 0.2 mg/kg EOW to the same dose
weekly (in 12 patients followed for< 120 months) [40]. One OS
publication reported stabilized eGFR in 21 male patients after 10
years [49]. Three CRs suggested that agalsidase alfa might slow the
decrease in eGFR [60,62,67] (Table 2).
In MG populations, eGFR did not change significantly with agalsi-
dase alfa. This was reported in 12 publications (five CT publications
including three RCTs [27,135,176] and two single-arm studies [26,35],
five OS publications [139,141,142,146,147] and two registry studies
[137,144]). The five CT publications included three pure agalsidase alfa
publications (one RCT [27] and two single-arm studies [35,136] in
8–44 patients followed for ≤24 months), and two mixed-ERT pub-
lications in which the agalsidase alfa arm data were reported separately
(one single-arm CT publication in which 100 patients were followed for
24 months [26] and one RCT where 36 patients were followed for ≥12
months [176]). The five OS publications included a large report (234
patients) and one long-term follow-up (57 months)
[139,141,142,146,147]. Of the registry studies, one followed 181 pa-
tients for 60 months and the other followed 314 patients for an average
of 17 months [137,144].
The effect of switching from agalsidase beta 1.0 mg/kg EOW to
agalsidase alfa 0.2 mg/kg EOW differed across four publications
[26,177,179,181]. Two publications (one single-arm CT including 40
male switch patients [26] and one OS including 7 male switch patients
[179]) described no (clinical) change in eGFR 24 months after
switching. One OS showed that eGFR was reduced in 37 patients, of
whom 20 were male, 12 months after switching [181], and was sta-
tistically significant decreased at 24 months after the switch [177].
3.3.1.2. Agalsidase beta 1.0 mg/kg EOW. Publications from three single-
arm CT publications [70,72,73] and two OS publications [79,82]
reported on the effect of agalsidase beta on eGFR. One single-arm CT
(in 13 patients followed for 5 months) reported a non-significant
decrease in eGFR [70], whereas another showed no change in eGFR
during agalsidase beta 1.0 mg/kg EOW or after a dose reduction to 0.3
mg/kg EOW (in 21 patients who received normal dosing for 6 months
and reduced dosing for 18 months) [72]. In one single-arm CT
publication that reported patient-level change in eGFR, eGFR
decreased in two of six patients, no change was observed in another
two of six, and an increase was seen in one of six patients (one patient
was not evaluable at follow-up) [73]. One large OS publication reported
that early agalsidase beta treatment initiation was associated with a
reduced slope of eGFR decline (in 151 patients followed for 24 months)
[82] and another OS (11 patients followed for 60–126 months) reported
a significantly lower eGFR decline in patients with lower proteinuria
before ERT [79]. In this study, temporary agalsidase beta dose
reduction resulted in a statistically significant decrease in eGFR
(compared with full-dose period, seven patients) [79] (Table 2). One
CR reported a decline in eGFR during 16 years of agalsidase beta
treatment [84].
In MG populations, the observation that agalsidase beta had a sta-
bilizing effect on eGFR was consistently reported in 12 publications
(one RCT with open-label extension [149] and two further open-label
extensions in the same patients [150,157] and one single-arm CT
publication [152] and eight OS publications
[159,163,165,175,177,180,181,188]). Two publications reported dif-
ferent effects of agalsidase beta dose reduction on eGFR: one OS pub-
lication reported a statistically significant decrease (105 patients fol-
lowed for 8–16 months) [181], whereas an RCT observed no effect (52
patients followed for 12 months or longer) [176].
3.3.1.3. Mixed ERT. Eight mixed-ERT OS publications (including some
large, long-term studies including ≤100 patients followed for ≤120
months) agreed that ERT might slow the decrease in eGFR
[51,103,104,107,109,112,114,116]. One large, long-term OS
publication reported that patients without proteinuria responded
better to treatment than patients with overt proteinuria (109 patients
followed for ≤116 months) [103]. Four CRs noted that eGFR remained
stable or decreased during mixed-ERT [125,130–132].
In MG populations, one OS publication reported a statistically sig-
nificant decline in eGFR following 80 months of mixed ERT (26 pa-
tients) [108], and another OS noted no statistically significant change
in eGFR for patients treated with agalsidase alfa 0.2 mg/kg EOW or
agalsidase beta 0.2 mg/kg EOW combined [180].
3.3.2. Albuminuria/proteinuria
3.3.2.1. Agalsidase alfa 0.2 mg/kg EOW. Agalsidase alfa was generally
reported to have no effect on proteinuria. These findings were reported
by two CT publications (first a randomized, placebo-controlled portion
in which 14 patients were followed for 6 months [36], and then an
open-label extension of 48–54 months in the same patients [39]) and
six OS publications [42–44,48,49,52], including three large registry
studies involving 77–115 patients with proteinuria data followed for
36–89 months [43,44,48]. One OS publication reporting the impact of
10 years of agalsidase alfa treatment noted no changes in patients
without baseline proteinuria but a statistically significant increase in
proteinuria in those with pre-existing proteinuria at baseline [49]. The
only statistically significant finding in the registry studies was an
increase in proteinuria in patients with chronic kidney disease stage 1
at baseline [44]. When the agalsidase alfa regimen was changed from
0.2 mg/kg EOW to 0.2 mg/kg weekly, there was a decrease in
proteinuria (OS publication [52]) (Supplementary Table 8).
Effects of agalsidase alfa on proteinuria were very variable across
five different CRs: two CRs showed improved proteinuria [56,62], two
described worsening [65,125], and one noted no change during treat-
ment [64]. In two CRs, the change in proteinuria was dependent on
agalsidase alfa dose: patients experienced an increase in proteinuria
with agalsidase alfa 0.2 mg/kg EOW dose but a decrease in proteinuria
when the dose was subsequently increased to 0.4 mg/kg EOW [63,67].
For MG populations, one RCT [176], one single-arm CT publication
[136] and three OS publications [139,142,147] reported no statistically
significant change in proteinuria with agalsidase alfa. Two OS pub-
lications reported the effect of switching from agalsidase beta 1.0 mg/
kg EOW to agalsidase alfa 0.2 mg/kg EOW on proteinuria/albuminuria
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Table 2
Glomerular filtration rate outcomes with approved doses of agalsidase alfa and agalsidase beta in adult male patients
Study, year [reference]
(number of patientsa)
Evidence gradeb
Male, n (%)c Duration
(months)
Units Baseline
(number of patientsd)
End-point
(number of patientse)
Overall result (p
value/
95% CI)
Alfa Beck et al. 2015
[41] (N=677)
Grade 3
360 (53) 60 mL/min/1.73 m2
(mean annualized eGFR
slope± SE)
eGFR at BL ≥60:
NR
(n=117)
eGFR at BL < 60:
NR
(n=18)
Proteinuria at BL
≥1.0 g/24 h:
Mean: 74.4
(n=16)
0.1–1.0 g/24 h:
Mean: 101.8
(n=74)
<0.1 g/24 h:
Mean: 105
(n=15)
eGFR at BL ≥60:
−1.68± 0.19
(n=117)
eGFR at BL < 60:
−2.86± 0.53
(n=18)
Proteinuria at BL
≥1.0 g/24 h:
−4.76± 0.56
(n=16)
0.1–1.0 g/24 h:
−1.62± 0.23
(n=74)
< 0.1 g/24 h:
−1.32± 0.48
(n=15)
↓ (95% CI −2.05,
−1.31)
↓ (95% CI −3.90,
−1.83)
↓ (95% CI
−5.85, −3.66)
↓ (95% CI −2.08,
−1.17)
↓ (95% CI −2.26,
−0.38)
Feriozzi et al. 2009
[43] (N=165)
Grade 3
115 (70) 36 mL/min/1.73 m2 94.5 [30.8]
(n=115)
81.2 [32.5]
(n=115)
↓ (p< 0.01)
Feriozzi et al. 2012
[44] (N=208)
Grade 3
134 (64) 60–134 mL/min/1.73 m2 97.3 [26.5]
(n=134)
79.7 [31.8]
(n=134)
↓ (p< 0.01)
Hughes et al. 2008
[29] (N=7)
Grade 1a
15 (100) 6 mL/min/1.73 m2
106.3± 13.9
(n=7)
Increase within normal
range:
106–131 mL/min
↑ (p=0.007)
Hughes et al. 2011
[48] (N=250)
Grade 3
172 (69) ≥48 mL/min/1.73 m2
(median [10−90th
percentile])
88.2
(41.1–137.0)
(n=105)
80.3
(34.2–119.7)
(n=105)
↓ (p< 0.001)
Kampmann et al. 2015
[49] (N=45)
Grade 3
21 (47) Median (range):
130
(115–150)
mL/min/1.73 m2 ≥90 mL/min/1.73
m2:
Values: NR
<90 mL/min/1.73
m2:
Values: NR
≥90 mL/min/1.73 m2:
10 years: NC
<90 mL/min/1.73 m2:
10 years: NC
NC (NS)
NC (NS)
Pastores et al. 2007
[35] (N=22)
Grade 1c
20 (91) Range:
2.5–15
mL/min/1.73 m2 Transplant pts:
64.5± 6
(n=12)
Transplant pts:
71.6± 8.0
(n=12)
↑ (p=0.07)
Schiffmann et al. 2001
[36] (N=14)
Grade 1a
14 (100) 5.5 Creatinine clearance mL/
min/1.73 m2 92.7± 6.2
(n=13)
94.8± 7.7
(n=13)
↑ (NR)
Schiffmann et al. 2006
[38] (N=26)
Grade 1c
26 (100) 18 mL/min/1.73 m2 97
(n=26)
90
(n=25)
↓ (p=0.38)
Schiffmann et al. 2006
[39] (N=25)
Grade 1c
25 (100) 48–54 mL/min/1.73 m2 88.4 [26.0]
(n=24)
Month 48:
75.1 [32.7]
(n=24)
↓ (p=0.039)
Schiffmann et al. 2007
[52] (N=12)
Grade 2
12 (100) 24–48 mL/min/
1.73 m2
77.8 [30.4]
(n=12)
53.7 [21.0]
Mean change:
−8.0 [2.8]/year
↓ (NR)
Beta Eto et al. 2005
[70] (N=13)
Grade 1c
13 (100) 4.6 Creatinine clearance mL/
min
126.6 [41.8]
(n=13)
115.3 [30.4]
(n=13)
↓ (p=0.216)
Kim et al. 2016
[79] (N=19)
Grade 2
15 (79)
11 adults,
4 paediatric pts
60–126 mL/min/1.73 m2 107.3 [28.5]
(n=11)
During shortage:
78.3 [29.4]
(n=7)
−3.8 [4.5]/year
(n=11)
Stratified by BL
proteinuria
< 0.1g/day:
−0.7 [3.8]/year
(n=3)
> 0.1 g/day:
−6.3 [4.2]/year
(n=6)
During shortage:
↓ (NR)
NC (NS)
NC (NS)
NC (p> 0.05)
(continued on next page)
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levels [179,181]: in one, there was a statistically significant increase in
albuminuria following the switch [181], and in the other, there was no
change in proteinuria [179].
3.3.2.2. Agalsidase beta 1.0 mg/kg EOW. There were two single-arm CT
publications [72,73] and two OS publications [79,80] which reported
proteinuria/albuminuria outcomes following agalsidase beta. One
single-arm CT publication reported no statistically significant changes
with agalsidase beta 1.0 mg/kg EOW or following a dose reduction to
0.3 mg/kg EOW in 21 patients followed for ≤18 months [72]. A
resolution of proteinuria was observed in all patients with follow-up
data available in a single-arm CT publication of six patients followed for
12 months [73]. In an OS publication in 11 patients followed for
60–126 months, there was no statistically significant effect of agalsidase
beta treatment on proteinuria, and no impact of baseline proteinuria on
treatment outcomes [79]. Another OS publication reported that one of
three patients had detectable proteinuria at baseline which resolved
during treatment [80] (Supplementary Table 8). Five CRs with
agalsidase beta showed an improvement in proteinuria
[86,88,92,95,96], whereas one showed no change [87], and one a
worsening [85].
One MG single-arm CT reported a decrease in proteinuria with
agalsidase beta when used in conjunction with antiproteinuric therapy
(angiotensin-converting enzyme inhibitor [ACEi] and/or angiotensin
receptor blocker [ARB]) [152]. Two OS publications [164,175] showed
a statistically significant reduction in proteinuria in 40 patients fol-
lowed for ≥60 months and a resolution of proteinuria in some patients
(in a small study of 11 patients followed for 29–58 months). One OS
publication reported a statistically significant decrease in proteinuria
with agalsidase beta in combination with paricalcitol [188]. One open-
label extension of a placebo-controlled RCT [157] and four OS pub-
lications [159,160,165,181] reported no statistically significant change
in proteinuria or albuminuria. In an RCT [176] and another OS pub-
lication [181], agalsidase beta therapy at a dose of 0.2 mg/kg EOW or
with a dose reduction to 0.3–0.5 mg/kg EOW did not result in
statistically significant changes in proteinuria and albuminuria.
3.3.2.3. Mixed ERT. The effects of mixed ERT on proteinuria/
albuminuria are supported by four mixed-ERT OS publications,
including one study investigating proteinuria in 109 patients after
116 months [103] and three smaller studies reporting changes in
albuminuria [51,107,109]. In one CR, the patient had slightly
elevated albuminuria levels at baseline, which decreased after 1 year
of agalsidase beta 1.0 mg/kg EOW and remained stable for the next 10
years (with different ERT regimens) [130]. Proteinuria was also
described in another two CRs [121,125].
In MG populations, there was one mixed-ERT OS publication in-
cluding renal dialysis and transplant patients that reported a non-sig-
nificant increase in proteinuria in transplanted patients [186].
3.4. Cardiac outcomes
3.4.1. Left ventricular mass (LVM)/left ventricular mass index (LVMi)
3.4.1.1. Agalsidase alfa 0.2 mg/kg EOW. Two RCT publications [27 and
the placebo-controlled 29] and four OS publications [41,48,49,189],
reported measures of LVM with agalsidase alfa therapy. In a small
placebo-controlled RCT with open-label extension in six patients using
magnetic resonance imaging (MRI) assessment of left ventricular mass
index (LVMi) (followed for 30 months), agalsidase alfa showed a
significant reduction in LVM compared with placebo [29]. In one
RCT that included 26 patients followed for 12 months, a non-significant
increase in LVM was seen with agalsidase alfa 0.2 mg/kg EOW, whereas
no change was seen with agalsidase alfa 0.2 mg/kg weekly and a non-
significant decrease with agalsidase alfa 0.4 mg/kg weekly [27]. In one
registry study publication (in 172 patients followed for ≥48 months, 45
of whom had had LVM data available), LVM decreased significantly in
the 22 patients with baseline LVH [48], and in another OS publication
(in 360 patients followed for 60 months, 71 of whom had LVMi data
available), the progression of LVH was slowed compared with untreated
patients, but still increased significantly [41]. After 10 years of
Table 2 (continued)
Study, year [reference]
(number of patientsa)
Evidence gradeb
Male, n (%)c Duration
(months)
Units Baseline
(number of patientsd)
End-point
(number of patientse)
Overall result (p
value/
95% CI)
63.3 [37.2]
(n=7)
Lubanda et al. 2009
[72] (N=21)
Grade 1c
21 (100) 5.5 mL/min/1.73m2 Median: 92.5
(n=21)
Median: 93.1
(n=21)
NC (NS)
Najafian et al. 2016
[73] (N=6)
Grade 1c
6 (100) 11–12 mL/min/1.73m2 Range: 111–154
(n=6)
Range: 114–190
(n=5)
NC/↓/↑ (NR)
Warnock et al. 2012
[82] (N=213)
Grade 3
151 (71) >24 mL/min/1.73 m2/year Q1f: 99 [22.6]
(n=37)
Q2: 77 [32.9]
(n=37)
Q3: 88 [38.7]
(n=38)
Q4: 2 [34.3]
(n=36)
Q1: −0.1 [1.20]
(n=38)
Q2: −2.1 [0.52]
(n=38)
Q3: −3.8 [0.61]
(n=38)
Q4: −6.7 [2.26]
(n=37)
↓ (NR)
Data are means (SD) or means± SE or medians (range), unless otherwise indicated.
Case series, case reports, mixed-ERT publications, paediatric-adult-mixed publications, and publications with other dose regimens are not included.
↓, decrease; ↑, increase; BL, baseline; CI, confidence interval; ERT, enzyme replacement therapy; eGFR, estimated glomerular filtration rate; h, hours; NC, no change;
NR, not reported; NS, not significant; pt, patient; Q1, first quartile (based on progression of renal disease during follow-up); Q2, second quartile; Q3, third quartile;
Q4, fourth quartile; SD, standard deviation; SE, standard error.
a Total number of patients included in the study who were treated with ERT;
b Study grades defined as follows: Grade 1a randomized controlled trial; Grade 1c single-arm clinical trial; Grade 1a/c randomized controlled trial with single-arm
open-label extension; Grade 2 prospective observational study; Grade 3 retrospective observational study; Grade 4 case series; Grade 5 case report;
c Number of male patients who were treated with ERT;
d Number of male, ERT-treated patients with data for the outcome at baseline;
e Number of male, ERT-treated patients with data for the outcome at endpoint;
f eGFR slope Quartile 1: −1.2 to 15.3, Quartile 2: −2.8 to -1.3, Quartile 3: −4.8 to −2.9, Quartile 4: −15.5 to −4.9.
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agalsidase alfa there was no change in LVMi in patients without
baseline LVH, but a statistically significant decrease in LVMi in
patients with baseline LVH (OS in 21 patients) [49]. In the final small
OS (four patients), switching from agalsidase beta 1.0 mg/kg EOW to
agalsidase alfa 0.2 mg/kg EOW led to a small decrease in LVM [189]
(Supplementary Table 9).
There were four CRs which reported an increase in LVH/LVMi with
agalsidase alfa after 12 months [61], 6 years [64], 9 years [57], and 12
years [60]. Another CR described stabilization of LVMi, indicated by
absence of progression to LVH, in one patient treated with agalsidase
alfa [59] and in another who switched regimens (from agalsidase alfa to
agalsidase beta and back to agalsidase alfa) [84]. Normalization of
hypertrophy after 6 years of treatment [68], and fluctuations in LVM
depending on dose, with a lower dose causing an increase in LVM and a
higher dose a decrease [63], were also found in CRs.
Two RCTs [27,176] and one single-arm CT publications [26] in MG
populations showed that LVM parameters remained stable. LVM was
reported to decrease in two registry publications: one in 314 patients
followed for 17 months [137] and the other in 181 patients followed for
60 months [144]. In one OS publication, the impact of agalsidase alfa
on LVMi was variable [143], while another reported no change in LVMi
when patients were switched from agalsidase beta 1.0 mg/kg to agal-
sidase alfa 0.2 mg/kg EOW [179].
3.4.1.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, five OS
publications reported LVH outcomes [7,76,79–81]. LVMi decreased
significantly in two large registry study publications [7,81]; LVM
decreased in 115 patients followed for 59 months which was a
statistically significant decrease in patients who started agalsidase
beta treatment at age<30 years; LVM increased, however, in
patients who started ERT at age ≥50 years [7]. LVM did not change
in the two smaller study publications (five to eleven patients followed
for 10–126 months) [76,79] (Supplementary Table 9). In four CRs LVMi
declined or stabilized with agalsidase beta [84,87,90,91].
LVM was reported in one MG RCT [176], one MG single-arm CT
publication [151] and 14 MG OS publications
[158–161,164–167,169,170,173,174,179,180], half of which reported
a statistically significant reduction in LVM with agalsidase beta. One of
these noted a statistically significant decrease from baseline in LVM
with ERT in patients without fibrosis, but no such effect in patients with
mild or severe fibrosis [174].
3.4.1.3. Mixed ERT. Findings from mixed-ERT studies were reported
across nine OS publications [101,104,107,109,110,112,113,114,116]
including a large study in 100 patients followed for 59–64 months
[114]. One OS publication showed that patients with an abnormal
baseline electrocardiogram (ECG) had a statistically significant increase
in LVMi, while patients with normal ECG at baseline did not experience
any statistically significant change in LVMi (neither progression nor
regression) with mixed-ERT treatment (6 years’ follow-up) [113]. One
CR noted a deterioration in LVMi [125] but three other CRs showed a
decline or stabilization in LVMi [122,124,127].
LVMi with mixed ERT was also described in one MG RCT [176],
another single-arm CT publication [26], and eight OS publications
[51,103,179,180,182,183,185,186]. In one of these OS publications (25
patients), there was a statistically significant decrease in LVM and LVMi
after 12 months [182]. In another mixed-ERT OS publication including
40 patients, LVM decreased in the first few years after treatment in-
itiation and increased thereafter (but neither change was statistically
significant) [183].
3.4.2. Left ventricular wall thickness (LVWT)
3.4.2.1. Agalsidase alfa 0.2 mg/kg EOW. One OS including 21 males
with mild hypertrophy, reported a statistically significant decrease in
LVWT after 10 years of treatment with agalsidase alfa [49], while two
CRs noted an increase in LVWT [57,64]. One OS reported a small
decrease in LVWT after switching from agalsidase beta 1.0 mg/kg to
agalsidase alfa 0.2 mg/kg EOW [189] (Supplementary Table 10).
In one large registry publication of a MG population of 314 patients,
there was decreased LVWT after 12 and 24 months of agalsidase alfa
[137]. In two OS publications, wall thickness measures did not change
on switching from agalsidase beta 1.0 mg/kg to agalsidase alfa 0.2 mg/
kg EOW (LVWT [179]; septal and posterior wall thickness [181]).
3.4.2.2. Agalsidase beta 1.0 mg/kg EOW. Wall thickness outcomes with
agalsidase beta were assessed in male patients in three OS publications.
One study showed a statistically significant decrease in maximal wall
thickness (MWT) and left ventricular end-diastolic diameter (LVEDD) in
44 patients followed for a median of 36 months [81]. Another OS in 10
patients followed ≤12 months reported no change in LVWT parameters
(MWT, LVEDD, and left ventricular end systolic diameter) [76],
whereas a third OS in three patients demonstrated that wall thickness
decreased in two patients and increased in one patient after 18 months
[80]. LVWT stabilized or decreased in two CRs [87,91] (Supplementary
Table 10).
For MG populations, agalsidase beta reduced LVWT parameters in
six publications (one single-arm CT [156] and seven OS publications
[159,164,167,170,173,174,179]). Agalsidase beta did not change
LVWT in four OS publications [163,166,171,181], including three large
studies of 56–105 patients followed for ≤58 months [163,171,181].
One of these noted that LVWT was stable in those who started therapy
at age< 40 years, but was significantly higher if patients received their
first dose of ERT when aged ≥40 years [163]. In one OS, agalsidase
beta dose reduction did not have a statistically significant effect on
posterior LVWT (median of 12 months’ follow-up) [181].
3.4.2.3. Mixed ERT. Two mixed-ERT OS publications [109,113] and
two CRs [122,126] indicated that LVWT parameters stabilized or
decreased in male patients.
In MG populations, there was one OS that demonstrated a statisti-
cally significant decrease in intraventricular septum thickness [IVST]
(25 patients treated for 12 months) [182], but three longer-term OS
publications (37 to 64 months) reported no change in LVWT
[184,185,187]. One mixed-ERT OS publication involving a MG popu-
lation of 34 patients followed for 45–48 months reported an increased
posterior LVWT in chronic haemodialysis patients and a decreased
posterior LVWT in renal transplant patients [186].
3.4.3. Left ventricular ejection fraction (LVEF)
3.4.3.1. Agalsidase alfa 0.2 mg/kg EOW. One placebo-controlled RCT
publication with open-label extension reported no change in LVEF
following 6 months of agalsidase alfa (seven patients) [29]. An OS
including 21 males reported no statistically significant change in LVEF
after 10 years of treatment with agalsidase alfa [49] (Supplementary
Table 11). One CR showed that the LVEF remained normal after 5 years
of treatment with agalsidase alfa [57].
Two OS publications of MG populations reported no change in LVEF
when patients were switched from agalsidase beta 1.0 mg/kg to agal-
sidase alfa 0.2 mg/kg EOW (105 patients followed for 8–16 months
[181] and ten patients followed for 20 months [179]).
3.4.3.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, one
registry OS publication reported a statistically significant
improvement in ejection fraction in 44 patients followed for a median
of 36 months [81]. One OS [80] and two CRs [86,88] also described an
improvement, but other CRs described stabilization [85] or worsening
in LVEF [90] (Supplementary Table 11).
In MG publications, there was no change in LVEF with agalsidase
beta in two single-arm CT publications [151,156] and nine OS pub-
lications [164,166–168,170,171,173,175,179] that included two large
studies (40 patients followed for ≥60 months [175]; and 56 patients
followed for ≤58 months [171]). One MG OS publication did report a
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small but statistically significant increase in ejection fraction [161].
Dose reduction (to 0.3–0.5 mg/kg EOW) was reported not to lead to a
change in LVEF in the large OS publication (in 105 patients followed for
8–16 months) [181].
3.4.3.3. Mixed ERT. One mixed-ERT OS reported no change in ejection
fraction in 26 male patients [113], whereas one CR showed an increase
[122].
In MG populations, the effect on LVEF was described in three OS
publications [177,183,185]. Only one of these studies (the large, long-
term study of 40 patients followed for 20–71 months) reported a de-
crease in ejection fraction in patients during the early years of ERT,
with no change in ejection fraction later in treatment [183].
3.4.4. Electrocardiogram (ECG) measures
3.4.4.1. Agalsidase alfa 0.2 mg/kg EOW. One placebo-controlled RCT
publication in 14 patients followed for 6 months [36] and another
placebo-controlled RCT (6 months) with open-label extension (24
months) in seven patients [29] reported a decrease in QRS duration
with agalsidase alfa. In a retrospective analysis including 21 males, one
patient developed conduction abnormalities during ERT [49]
(Supplementary Table 12). One CR described occurrence of persistent
atrial fibrillation [59], another noted an increase of QRS voltages with
deeply negative T waves after 9 years of treatment [57] and a third
showed ST-segment depression and negative T waves [64]. There were
no publications describing changes in ECG measures with agalsidase
alfa from MG publications.
3.4.4.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, one
single-arm CT publication reported no change in ECG measures in
three patients treated with agalsidase beta 1.0 mg/kg EOW and 12
patients treated with different agalsidase beta dosing regimens, all
followed for 2.5 months (reported as a safety parameter in this study)
[69]. One large registry OS publication (in 44 patients followed for a
median of 36 months) reported a statistically significant increase in P
wave duration and PQ interval and a statistically significant decrease in
heart rate-corrected QT interval [81]. Another OS of three patients
followed for 18 months reported that ECG measures did not change
[80] (Supplementary Table 12). In a CR, ECG signs of cardiac
hypertrophy were reduced [85].
For MG populations, there were no changes in ECG measures, such
as PR and QRS intervals, following agalsidase beta in one relatively
large placebo-controlled RCT with an open-label extension (in 58 pa-
tients followed for 26 months) [149]), and two OS reports [160,168].
3.4.4.3. Mixed ERT. For mixed ERT, two OS publications reported that
ECG measures did not change [113,116].
One large mixed-ERT OS publication (in 40 patients followed for
20–71 months) did not demonstrate statistically significant changes in
PQ time or QRS duration in patients in the first years of ERT. However,
patients analysed after some years of ERT had increased QRS duration
and a trend towards increased PQ time [183].
3.4.5. Exercise testing
3.4.5.1. Agalsidase alfa 0.2 mg/kg EOW. For agalsidase alfa, there were
no publications reporting data from clinical or OS publications for male
patients. One CR of a male patient demonstrated worsened cardiac
symptoms, as indicated by worsening of New York Heart Association
(NYHA) functional classification to class 3, after 5 years of treatment
with agalsidase alfa [57].
In an MG population, one RCT publication on 44 patients followed
for 12 months showed no change in exercise testing with agalsidase alfa
0.2 mg/kg EOW, 0.2 mg/kg weekly, and 0.4 mg/kg weekly [27].
3.4.5.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta there were
no publications reporting data for male patients. In MG populations,
one single-arm CT publication [156] and one OS publication [159]
reported no statistically significant changes in exercise testing. In
contrast, two OS publications demonstrated improvements in the
bicycle stress test [168,174] and one OS publication demonstrated an
improvement in NYHA class [170].
3.4.5.3. Agalsidase beta 1.0 mg/kg EOW. One mixed-ERT OS
publication of an MG population reported no change in exercise
testing [184].
3.5. Nervous system outcomes
3.5.1. Sweat function
3.5.1.1. Agalsidase alfa 0.2 mg/kg EOW. One publication describing
30–36 months' follow-up of 26 patients treated during a placebo-
controlled RCT reported immediate effects of agalsidase alfa on the
ANS [37]. In the short term (24–72 hrs) after a single agalsidase alfa
(0.2 mg/kg) infusion, there was a statistically significant temporary
improvement in sweat function, which returned to pre-infusion
treatment levels after 7 days [37]. One single-arm CT [31] and two
OS publications [42,48] (in 4–97 patients followed for 12–48 months)
reported improvements in sweat function and two OS publications (in
11–22 patients followed for 24–36 months) reported no change in sweat
function [45,52]. Improvements in sweat function were reported in one
CR of a male patient for agalsidase alfa [67] (Supplementary Table 13).
In MG publications, one RCT publication reported a non-significant
increase in sweat volume with 0.1 mg/kg weekly and 0.2 mg/kg weekly
compared with 0.2 mg/kg EOW agalsidase alfa [135]. In one registry
OS publication (in 40 patients followed for 28–150 months), there was
no change in sweat function in patients who switched from agalsidase
beta to agalsidase alfa [100].
3.5.1.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, one
single-arm CT publication (in 15 patients, of whom three received the
approved dose, followed for 2.5 months) [69], and one OS publication
(in 22 patients followed for ≤23 months) [77] reported subjective
improvements in sweat function (Supplementary Table 13).
Improvements in sweat function with agalsidase beta were also
reported in three CRs in male patients [85,88,97].
In MG publications, improvements in hypohidrosis were reported in
two OS publications: one study in 40 patients followed for ≥60 months
[175] and another study in 11 patients followed for 29–58 months
[164]. In one OS publication (in 40 patients followed for 28–150
months), there was no change in sweat function between patients
switching from regular-dose to reduced-dose agalsidase beta (0.5 mg/
kg EOW) [100].
3.5.1.3. Mixed dose. Two CRs in male patients reported improvements
in sweat function with mixed ERT [127,129].
3.5.2. PNS nerve sensitivity
3.5.2.1. Agalsidase alfa 0.2 mg/kg EOW. PNS nerve sensitivity with
agalsidase alfa was reported in one single-arm CT publications [40] and
two open-label extensions of an RCT [37,38]. After 12–18 months
follow-up there was a statistically significant reduction in intra-
epidermal nerve fibre density (IENFD), and no change in thermal
thresholds in 26 patients [38]. When the same 26 patients were
followed for 30–36 months, there was a statistically significant
reduction in cold and warmth detection thresholds [37]. In a single-
arm CT, switching from EOW dosing to weekly dosing of agalsidase alfa
0.2 mg/kg resulted in a worsening of warmth perception, although cold
perception did not change (12 patients followed for ≤120 months)
[40]. Two single-arm CT publications in the same patients reported no
change in neurological examination scores after 12 months [30] and 24
months [31] (Supplementary Table 14). One CR described
improvements in heat intolerance with agalsidase alfa [129].
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For MG populations, there were two OS publications that reported
no change in PNS nerve sensitivity following the switch from agalsidase
beta 1.0 mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW [100,181]: one
study measured heat or cold tolerance in 40 patients after 28–150
months [100].
3.5.2.2. Agalsidase beta 1.0 mg/kg EOW. With agalsidase beta, nerve
sensitivity was reported to significantly improve in one OS (of 22
patients followed for 18–23 months) [77] (Supplementary Table 14).
One CR described improvements in sensory ulnar and sural nerve
conduction with agalsidase beta [97].
In MG publications, there was no change in heat/cold tolerance or
PNS nerve sensitivity when the agalsidase beta dose was reduced
[100,181].
3.5.2.3. Mixed ERT. In a mixed-ERT OS publication, patients
experienced an improvement in IENFD (18 patients followed for
≤103 months) [117].
3.5.3. Vestibular/auditory and other CNS outcomes
3.5.3.1. Agalsidase alfa 0.2 mg/kg EOW. Improvements in vestibular/
auditory symptoms reported with agalsidase alfa were described in two
CT publications: one was a placebo-controlled RCT with an open-label
extension in seven patients followed for 24–30 months [28], and the
other was a single-arm CT in five male patients followed for 12 months
[34]. During the RCT portion, patients receiving placebo experienced a
greater decline in hearing compared with the treated group, but the
difference between groups was not statistically significant [28]. During
the open-label portion, the placebo patients crossed over to agalsidase
alfa and all patients experienced an improvement in hearing [28]. One
OS publication reported stabilization of hearing in 11 patients followed
for 25–73 months [53] (Supplementary Table 15). Neurological
examination findings did not change with agalsidase alfa in one
single-arm CT publication (in seven patients followed for 12 months)
[30]. Two publications from the same placebo-controlled RCT in 14
patients followed for 6 months reported changes in cerebral blood flow
with agalsidase alfa and placebo [32,33]. In both publications, cerebral
blood flow decreased with agalsidase alfa and increased in the placebo
group (Supplementary Table 15).
In MG publications, a significant improvement in hearing with
agalsidase alfa was reported in one publication describing an RCT and
its open-label extension [134] and in one OS publication [145], but no
change in auditory function was reported in another publication [138].
One single-arm CT with agalsidase alfa reported no change in neuro-
logical examination scores [136].
3.5.3.2. Agalsidase beta 1.0 mg/kg EOW. Hearing loss improved with
agalsidase beta in one CR [85] but worsened in another [91]. One OS
found that neurological examination scores remained stable in patients
who had normal scores at baseline and were followed for 18–23 months
while receiving agalsidase beta [77] (Supplementary Table 15).
In a MG population, one OS showed no change in auditory function
[160].
3.5.3.3. Mixed ERT. One mixed-ERT OS publication reported a
decrease in hearing loss [115], another described an increased risk
for tinnitus in those who were ERT antibody-positive [107], and a third
reported no significant worsening in hearing acuity [105].
3.5.4. White matter hyperintensities (WMH)
3.5.4.1. Agalsidase alfa 0.2 mg/kg EOW. A CR (41-year-old male) with
CNS lesions at baseline (vascular dolichoectasia with punctuated WMH
in frontal lobe and basal ganglia) described no change in CNS lesions
after 52 months of agalsidase alfa (two different doses: 0.2 mg/kg and
0.4 mg/kg) [63]. In a MG population, one single-arm CT publication (in
eight patients followed for 24 months) also reported no change in WMH
with agalsidase alfa [136].
3.5.4.2. Agalsidase beta 1.0 mg/kg EOW. In one CR of a male patient
receiving agalsidase beta, treatment resulted in disappearance of most
WMH [99], but another showed an increase in WMH (with full and
lower dose) [84]. One MG OS publication (in 25 patients followed for a
median of 27 months) showed that, in younger patients (age<50
years), WMH remained stable in 44% of patients treated with agalsidase
beta compared with 31% of patients receiving placebo [162]. Another
MG OS reported no change in existing ischaemic brain lesions and no
new brain lesions (in six patients followed for ≥120 months) [165].
3.5.4.3. Mixed ERT. One OS publication (in 27 patients followed for 66
months) [112] and one case study [84] described the development of
WMH with mixed ERT. One OS investigated WMH and other brain
pathology using positron emission tomography and MRI over 9 years in
patients who received mixed ERT (agalsidase beta 1.0 mg/kg EOW who
were switched to agalsidase alfa 0.2 mg/kg EOW during the temporary
shortage). Of 32 patients, only six received a scan before and after start
of treatment and only four patients showed progression of pathology
during treatment [123].
3.5.5. Stroke/transient ischaemic attack (TIA)
Long-term and large-scale trials would be required to show any
influence of ERT on stroke and/or TIA. However, these are difficult to
perform in Fabry patients. Currently, the only publications available
report on the number of patients with stroke/TIA, but none of them
compares the number of strokes and/or TIAs per patient per year before
and after ERT (agalsidase alfa: [30,39,50,59,136,137,144,147]; agal-
sidase beta: [148,150,157,159,163,175]; mixed ERT:
[26,108,111,112,114,118,120,123,127,128,177,181,186]).
3.6. Pain outcomes
3.6.1.1. Agalsidase alfa 0.2 mg/kg EOW. With agalsidase alfa,
improvements in subjectively assessed acroparaesthesiae were
reported in one single-arm CT publication (in seven patients followed
for 24 months) [31]. In a placebo-controlled RCT, 14 patients treated
with agalsidase alfa experienced a decrease in pain and pain-related
QoL while data in the 12 patients receiving placebo remained mostly
unchanged [36]. Significantly improved pain scores were reported in
14 patients followed for 6 months [36]. The open-label extension study
where the same patients were followed for a further 30 months reported
no further decline in pain scores [37]. A large registry OS publication
(in 345 patients, of whom 51 had Brief Pain Inventory [BPI] data
available) followed for ≤36 months) showed improvements in average
pain and present pain assessed with the BPI, but no changes in worst
pain and last pain [47]. Improvements in neuropathic pain/
acroparaesthesiae were seen in one OS publication with agalsidase
alfa (in four patients followed for 12 months) [42]. In contrast, three
other OS publications did not report statistically significant changes in
pain scores (in 11 patients followed for 25–73 months [53], in 172
patients followed for 48 months in a registry study [48], and in five
patients followed for ≤12 months [55]) (Supplementary Table 16).
Most of the CRs of agalsidase alfa also described improvements in
neuropathic pain/acroparaesthesiae or pain scores [58,60–62,64].
One MG RCT publication reported an improvement in ‘pain-at-its
worst’ scores with agalsidase alfa 0.1 mg/kg/week and 0.2 mg/kg/
week compared with pre-treatment levels, but no differences in mean
pain score [135]. Two large registry OS publications reported reduc-
tions in BPI pain scores during ERT (in 181 patients followed for 60
months [144], and in 314 patients followed for a mean of 17 months
[137]). One RCT publication reported no change in pain with agalsi-
dase alfa [176], which was also seen in an OS publication in which
patients switched from agalsidase beta 1.0 mg/kg EOW to agalsidase
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alfa 0.2 mg/kg EOW [177]. One registry OS publication (in 40 patients
followed for 28–150 months) reported no change in pain in patients
who switched from agalsidase beta 1.0 mg/kg EOW to agalsidase alfa
0.2 mg/kg EOW [100]. One large OS publication (in 105 patients fol-
lowed for 8–16 months) reported statistically significant increases in
pain attacks when switching from agalsidase beta 1.0 mg/kg EOW to
agalsidase alfa 0.2 mg/kg EOW [181].
3.6.1.2. Agalsidase beta 1.0 mg/kg EOW. With agalsidase beta, one
single-arm CT publication reported a statistically significant
improvement in pain scores (in 15 patients across all five dosing
regimens followed for 2.5 months) [69], while another single-arm CT
publication reported a near-significant reduction in pain intensity (in
13 patients followed for 5 months) [70]. One OS also found that
treatment with agalsidase beta for 18 or 23 months significantly
reduced the mean total symptom score for neuropathic pain in a
group of 22 Fabry disease patients [77]. Pain was also improved in
an OS of three patients after 18 months [80] (Supplementary Table 16).
Many CRs with agalsidase beta also described reduced neuropathic
pain/acroparaesthesiae or improved pain scores [84,85,89,97].
In MG publications with agalsidase beta, improvements in pain
scores were reported from a placebo-controlled RCT with open-label
extension in 58 patients [149], who were then followed through open-
label extension studies for a further 30 months [157] and 54 months
[150], and one RCT publication using a reduced dose of 0.2 mg/kg
EOW [176]. During the placebo-controlled portion of the RCT, patients
in both groups experienced a decline in pain scores due to a possible
placebo effect, so the difference between groups was not statistically
significant [149]. In one single-arm CT, patients were able to dis-
continue their use of analgesics [151]. Three OS publications reported
decreased pain with agalsidase beta: reduction in neuropathic pain (40
patients followed for ≥60 months) [175], resolution of neuropathic
pain [164] and reduction in acroparaesthesiae [168]. No change in pain
symptoms was reported for agalsidase beta 1.0 mg/kg EOW, but low-
ering the dose to 0.3–0.5 mg/kg EOW resulted in an increase in pain
crises and pain attacks in the relatively large OS in 105 patients fol-
lowed for 8–16 months [181]. Another registry OS publication (in 40
patients followed for 28–150 months) reported no change in pain in
patients who switched from regular- to reduced-dose agalsidase beta
[100].
3.6.1.3. Mixed ERT. One mixed-ERT OS publication observed a greater
improvement in pain scores in ERT antibody-negative patients
compared with antibody-positive patients [107]. Most of the mixed-
ERT CRs described improved pain [119,124,125,127,129]. In one CR,
two patients showed an increase in pain scores after switching from
agalsidase beta 1.0 mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW,
which was reversed when agalsidase beta 1.0 mg/kg EOW was
reintroduced [125]. Furthermore, patients receiving agalsidase beta
1.0 mg/kg EOW were able to stop anti-neuropathic treatment or reduce
medication, whereas those receiving agalsidase alfa 0.2 mg/kg EOW
continued using carbamazepine during the study [125]. An 18-year-old
male had acral pain at baseline, which was reduced with agalsidase
beta (1.0 mg/kg EOW) but markedly increased when the patient was
switched to agalsidase alfa 0.2 mg/kg EOW [130].
One mixed-ERT MG OS publication reported a reduction in acro-
paraesthesiae [184]. In one OS, there was a statistically significant as-
sociation between time on mixed ERT and pain interference score, but
no significant association with pain severity [103].
3.7. Gastrointestinal (GI) outcomes
3.7.1. Agalsidase alfa 0.2 mg/kg EOW
Improvement in GI outcomes (i.e. abdominal pain, constipation,
nausea, and vomiting) with agalsidase alfa was reported in one single-
arm CT (five patients followed for 24 months) [31] and two OS
publications (in 33 male patients followed for 24 months [46] and in up
to 77 male patients followed for on average 48 months in a registry
study [48]) (Supplementary Table 17). Most (4 of 5) CRs with agalsi-
dase alfa also observed reduced GI outcomes [59,62,67,190] but one CR
described worsening abdominal pain, bloating, postprandial vomiting,
and sporadic diarrhoea after 4 years of treatment [65].
One CT publication in an MG population reported a reduction in the
number of patients with abdominal pain and/or diarrhoea during
treatment with agalsidase alfa [140]. Switching from agalsidase beta
1.0 mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW resulted in an in-
crease in GI pain in two relatively large, mixed-ERT OS publications (in
105 patients followed for 8–16 months [181], and in 89 patients fol-
lowed for 24 months [177]).
3.7.2. Agalsidase beta 1.0 mg/kg EOW
With agalsidase beta, improvement of GI outcomes (i.e. abdominal
pain, diarrhoea, and discontinuation of GI medications) was reported in
three CRs [74,85,97].
In MG publications, agalsidase beta resulted in an improvement in
GI outcomes in one single-arm CT publication [151] and resolution of
abdominal pain in one OS publication [164]. In one relatively large OS,
there was no change in GI pain and diarrhoea with regular-dose agal-
sidase beta, but dose reduction led to increased GI pain (in 89 patients
followed for 24 months) [177]. A relatively large, mixed-ERT OS pub-
lication reported no changes in GI outcomes (general or pain/diar-
rhoea) with regular- or reduced-dose agalsidase beta (in 105 patients
followed for 8–16 months) [181].
3.7.3. Mixed ERT
Positive effects of ERT on GI outcomes were confirmed in a mixed-
ERT OS publication in which diarrhoea was reduced in antibody-ne-
gative patients (in 24 patients followed for ≤131 months) [107], and in
one CR [127]. Another CR noted that GI discomfort was reduced with
agalsidase beta 1.0 mg/kg EOW but increased when the patient was
switched to agalsidase alfa 0.2 mg/kg EOW [130].
One mixed-ERT OS publication reported no changes in GI outcomes
(general or pain/diarrhoea) after switching from regular- to reduced-
dose agalsidase beta or regular-dose agalsidase alfa (in a registry study
of 40 patients followed for 28–150 months) [100].
3.8. Quality of life (QoL)
3.8.1. Agalsidase alfa 0.2 mg/kg EOW
One large registry OS publication (in 172 patients, of whom 30–37
had QoL data, followed for on average 48 months) reported non-sig-
nificant improvements in health scores from the 5-dimension EuroQol
questionnaire and EuroQol visual analogue scale with agalsidase alfa
[48]. Another relatively large, mixed-ERT registry OS publication re-
ported no change in self-reported energy levels (using the 36-Item Short
Form Health Survey [SF-36]) with agalsidase alfa (in 32 patients
treated for 12 months with agalsidase alfa) [100]. One mixed-ERT OS
publication reported no statistically significant difference in SF-36
scores after a switch from agalsidase beta 1.0 mg/kg EOW to agalsidase
alfa 0.2 mg/kg EOW [54] (Supplementary Table 18). A CR described an
increase in motivation after 12 months with agalsidase alfa [66].
In MG publications, findings varied. In two RCTs, QoL measures did
not change with agalsidase alfa 0.2 mg/kg EOW, 0.1 mg/kg weekly, or
0.2 mg/kg weekly [135], or with agalsidase alfa 0.2 mg/kg EOW, 0.2
mg/kg weekly, or 0.4 mg/kg weekly [27], but did increase (measured
using the EuroQoL index) with agalsidase alfa 0.2 mg/kg EOW in a
large registry OS publication (in 181 patients followed for 60 months)
[144]. There was no change in Center for Epidemiologic Studies De-
pression Scale (CES-D) score upon switching from agalsidase beta 1.0
mg/kg EOW to agalsidase alfa 0.2 mg/kg EOW in one relatively large,
mixed-ERT OS publication (in 105 patients followed for 8–16 months)
[181].
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3.8.2. Agalsidase beta 1.0 mg/kg EOW
For agalsidase beta, two single-arm CT publications reported im-
provements in general and mental health using the SF-36 (statistically
significant in 13 patients followed for 5 months [70]), and improve-
ments in bodily pain, general health, and vitality in the SF-36 (in 15
patients, three of whom received 1.0 mg/kg EOW, followed for 2.5
months [69]) (Supplementary Table 18). One registry OS publication
(in 71 patients followed for an average of 81 months) reported a sta-
tistically significant improvement in mental and physical health (using
the SF-36) after 12 months of agalsidase beta [83]. One mixed-ERT
registry OS publication reported a decrease in self-reported energy le-
vels (using the SF-36) when the agalsidase beta dose was reduced to
0.3–0.5 mg/kg EOW (in 32 patients followed for 18–74 months) [100]
(Supplementary Table 18). One CR demonstrated the resolution of a
diagnosis of depressive disorder after 12 months of agalsidase beta
[97], while another CR showed improvements in functional in-
dependence (using the Functional Independence Measure) in six pa-
tients with agalsidase beta [98].
For MG publications with agalsidase beta 1.0 mg/kg EOW, one
placebo-controlled RCT with open-label extension [149] in 58 patients,
two open-label extension studies (where the same patients were fol-
lowed for a further 30–36 months [157] and up to 54 months [150]),
and one OS publication [165] described improvements in QoL (using
the SF-36). A different OS publication (nine patients followed for 24
months) reported no change [168].
3.8.3. Mixed ERT
One mixed-ERT OS publication reported no statistically significant
difference in CES-D scores [117].
In MG populations, a relatively large, mixed-ERT OS publication in
105 patients followed for 8–16 months reported no change in QoL
[181]. Another mixed-ERT registry OS publication (in 32 male patients
followed for 18–74 months) reported no change in QoL between pa-
tients switching from regular- to reduced-dose agalsidase beta and pa-
tients switching from regular-dose agalsidase beta to regular-dose
agalsidase alfa [100].
3.9. Clinical events
Large, long-term trials are needed to show an effect of ERT on in-
cidence rates of clinical events, such as renal, cardiac, and cere-
brovascular events, and death. The majority of papers describing clin-
ical events before or during ERT only report the number of events
occurring during the study without a statistical analysis of the data.
There were no agalsidase alfa publications describing an ERT effect on
clinical events. One placebo-controlled RCT [148], one publication in
which patients were treated during an RCT, its open-label extension and
then followed through a registry [163], and two large OS publications
[78,172] reported an effect of agalsidase beta 1.0 mg/kg EOW on the
timing and incidence of severe clinical events. One large CT with 52
patients (including two severely affected females) showed that during
10 years of treatment 81% of patients did not experience any severe
clinical event and 94% of patients were still alive at the end of the study
[163]. One OS publication described a decrease in incidence rate of
severe clinical events after 6 months of treatment, which was sustained
during the remaining 4.5 years of the study [172]. Two registry OS
publications showed that the risk of a clinical event was significantly
lower when treatment was started at a younger age (< 40 years)
[78,172], and one placebo-controlled RCT demonstrated a significant
81% risk reduction for life-threatening events compared with placebo
when treatment was started before renal deterioration [148].
3.10. Male patients with later-onset phenotypes
Patients with later-onset phenotypes of Fabry disease often present
with later-onset symptoms that may be confined to a single-organ
system. Although several publications may describe outcomes for a mix
of patients, including patients with classic disease, later-onset disease or
variants of unknown significance, we identified outcome data specific
for adult male patients with later-onset phenotypes of Fabry disease in
five mixed-ERT MG OS publications. These studies included three small
studies of eight to 35 patients followed for 3–90 months [105,109,115],
a relatively large study in 109 patients followed for ≤116 months
[103], and one study describing the results from three patients who
switched from agalsidase beta 1.0 mg/kg EOW to agalsidase alfa 0.2
mg/kg EOW, and 13 patients who received agalsidase alfa 0.2 mg/kg
EOW [110]. Findings from these studies are outlined below.
For 18 patients (13 males and five females) with a predominantly
cardiac phenotype (IVS4+919G>A) who received agalsidase alfa or
beta for 6–39 months, echocardiography revealed the reduction or
stabilization of LVMi, IVST, and left posterior wall thickness (LPWT)
[109]. However, since this mutation affects mRNA splicing, it may not
be representative for the late-onset cardiac variant in patients with
missense later-onset mutations in the coding GLA regions.
In another study of 16 patients with a predominantly cardiac phe-
notype (IVS4+919G>A) who received agalsidase alfa or beta for at
least 12 months, LVMi decreased or remained stable [110]. In a rela-
tively large study including 37 male later-onset type patients followed
for ≤116 months, ERT (with agalsidase alfa or beta) was reported to
reduce LVMi and improve eGFR [103].
No publications containing data for male patients with later-onset
phenotypes who received ERT were identified in this analysis for ur-
inary (lyso-) GL-3, kidney or cardiac GL-3, or GL-3 levels in other or-
gans, ECG measures or exercise testing, other ANS, PNS, or CNS out-
comes, GI symptoms, or QoL.
4. Discussion
This systematic literature review includes all types of publication
with original data, any type of ERT regimen, and all Fabry disease-
related outcomes in the population of male Fabry patients over the past
16 years. Spanning 166 publications including 36 CTs, it provides a
comprehensive overview of outcomes achieved in male patients with
Fabry disease when treated with disease-specific therapy.
Analyzing this volume of evidence was a huge undertaking, adding
to the current literature in Fabry disease. First, it provides an overview
of all the evidence published exclusively in male patients. Previous
systematic literature reviews [197] have pooled data in male and fe-
male patients, which may not be appropriate considering the re-
cognized differences in clinical manifestations and disease progression.
Secondly, data from the current review in males and two other pub-
lications, in females [22] and paediatric patients [23], informed the
development of new therapeutic goals for Fabry disease [24]. This
therapeutic goals publication outlines what patients should expect to
achieve in each organ system, depending on their individual disease
status at baseline [24]. The therapeutic goals publication was based on
the evidence published in males (current review, total 166 publications
including 36 RCTs), in females (total 67 publications including 6 RCTs)
and paediatric patients (total 16 publications, including 6 RCTs). As the
reader can note, most of the evidence is derived from the current re-
view, in male patients. Finally, the current review provides a compre-
hensive summary of the effects of ERT on all organ systems. This helps
inform clinical decision-making and the management of male Fabry
patients.
ERT was the first disease-specific therapy available that changed the
natural history of Fabry disease. Data published in adult male patients
with Fabry disease demonstrates that the effect of ERT on plasma GL-3
levels, eGFR, and cardiac outcomes is strongest and substantiated by a
wide range of publications, showing consistent, dose-dependent re-
ductions in GL-3 accumulation, a reduced decline in eGFR, and im-
provements in cardiac outcomes (see relevant sections within the cur-
rent review). Furthermore, ERT may improve nervous system, GI, pain,
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and QoL outcomes. In the context of a multisystemic condition, the
impact of ERT on all affected organs is important and relevant. Some
studies show no change in outcomes over time with ERT. However,
considering the fact that Fabry disease is a lifetime progressive debili-
tating disease associated with a risk of premature mortality, no change
in outcomes is an indication of disease stabilization. This indicates that
a clinical benefit in preventing disease progression and avoiding dete-
rioration of patients’ well-being is seen when no difference in outcomes
after ERT compared with baseline is observed.
Patients who started ERT at an earlier age achieved better outcomes
[7,82,130,163,174], and, therefore, effective early treatment is needed
to prevent or mitigate disease progression [196]. Regarding cardiac
function, patients who started agalsidase beta treatment at age<30
years experienced a statistically significant decline in LVM but those
who started ERT at age ≥50 years reported an increase in LVM [7], and
patients< 40 years of age at treatment initiation had stable LPWT and
IVST over a period of 10 years, whereas patients ≥40 years of age at
treatment initiation significantly progressed over time [163]. Likewise,
the importance of administering ERT early was demonstrated in pa-
tients without fibrosis at baseline. They experienced a statistically sig-
nificant decline from baseline in LVM and a statistically significant
improvement in exercise capacity with ERT, while patients in whom
treatment was started when mild or severe fibrosis was already present
experienced no effect of ERT [174]. Regarding renal function, initiation
of treatment before the development of significant glomerulosclerosis
and proteinuria might prevent future renal disease [79,163], which
correlates with the reduced slope of eGFR decline that is seen in pa-
tients who started ERT early compared with a higher slope of eGFR
decline in patients who started ERT later [82]. Furthermore, two recent
publications derived from the Fabry Registry demonstrated a statisti-
cally significantly lower risk of clinical events in patients who started
ERT<40 years of age compared with those who were older at start of
ERT [78,172], and one placebo-controlled RCT showed that ERT in-
itiation before the start of severe organ damage gives a lower risk of the
occurrence of clinical events [148]. On a smaller scale, a case series
noted that the GL-3 clearance from podocytes was more extensive in the
patient who started ERT at 7 years of age compared with the patient
who started at 18 years [130].
Consolidated evidence suggests a dose effect. Studies which have
included both agalsidase alfa 0.2 mg/kg EOW and agalsidase beta 1.0
mg/kg EOW show more notable reductions of plasma GL-3, plasma
lyso-GL-3, and urinary GL-3 with agalsidase beta 1.0 mg/kg EOW
[101,102]. A dose increase of agalsidase alfa beyond the approved dose
has a positive effect on several outcomes including plasma GL-3
[27,52], urinary GL-3 [52], eGFR [40], proteinuria [52,62,67], and
sweat function [135]. In contrast, reducing the agalsidase beta dose or
switching from agalsidase beta 1.0 mg/kg EOW to agalsidase alfa 0.2
mg/kg EOW, negatively impacts some outcomes. The literature shows
that agalsidase beta dose reduction causes worsening of plasma (lyso-)
GL-3 plasma [54,72], urinary GL-3 [72], renal GL-3 [72], pain [181], GI
symptoms [177], and self-reported energy levels [100]. Furthermore,
the switch from agalsidase beta (1.0 mg/kg EOW) to agalsidase alfa (0.2
mg/kg EOW) also had a negative impact on plasma lyso-GL-3 [54],
urinary GL-3 [26], renal GL-3 [130], albuminuria [181], pain
[125,130], and GI symptoms [130,177,181]. A dose effect is further
exemplified by a normalization of plasma GL-3 levels with agalsidase
beta 1.0 mg/kg EOW in several studies (Supplementary Table 2)
[69,70,72,75,79,102]. The largest head-to-head comparison between
agalsidase alfa and agalsidase beta demonstrated that 19.4% of patients
on agalsidase alfa and 13.3% of patients on agalsidase beta progressed
to a composite clinical endpoint (renal, cardiovascular, or cere-
brovascular events, or death) during the 59-month study duration, al-
though differences were not significant due to limited power [114].
The design and limitations of the systematic literature analysis,
which was used to identify and extract the data reported in this pub-
lication, are described in detail in a separate manuscript [21]. Data
reported in patients with later-onset Fabry disease largely reflect the
outcomes seen in classic male patients. However, many publications
included in our analysis may have described outcomes for a mix of
patients with classic disease, later-onset disease or variants of unknown
significance, or did not specify whether patients had classic or later-
onset disease. Therefore, the inclusion of patients with later-onset
phenotypes in clinical studies looking at outcomes related to organs
that are not affected in such patients could be a source of error. Our
review was limited to ERT and did not include all the emerging treat-
ment approaches for Fabry disease such as migalastat [191–193] and
PRX-102 [194]. Furthermore, our analysis did not stratify the renal or
cardiac outcomes according to concomitant medications, which may be
relevant considering the effect of medications used to treat renal disease
(ACEi and/or ARB) on the progression of Fabry nephropathy [195].
Furthermore, the use of antiproteinuric therapy is only reported for
about half of the publications that report on albuminuria or proteinuria,
which is important for putting results in perspective.
ERT, available since 2001, was the first disease-specific treatment
for Fabry patients, providing a clinical benefit to thousands of patients
to date with this rare disease. Fabry disease is a multisystemic disease
and ERT has an effect on most outcomes and organ systems, resulting in
slowing or halting of cardiac and renal disease progression. Evidence,
mainly derived from male studies, shows that patients may benefit from
treatment that starts early, before major organ damage has developed.
Consolidated evidence suggests a dose effect. Together, the data de-
scribed in male, female, and paediatric patient populations inform
clinical practice in order to facilitate individualized treatment, aiming
for optimized patient care and improvement in QoL.
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